Association analysis between type 2 diabetes and the gut microbiota: a community-based cross-sectional study in Japan
DOI:
https://doi.org/10.51094/jxiv.105Keywords:
gut microbiota, type 2 diabetes, Lactobacillales, community-based cross-sectional studyAbstract
There are a few studies on the association between type 2 diabetes (T2D) and the gut microbiota but no community-based cross-sectional study. In the Iwaki Health Promotion Project (Hirosaki, Japan), we surveyed medical information and lifestyle and analyzed the gut microbiota using the terminal restriction fragment length polymorphism technique or next-generation sequencing. Based on these data, multivariable logistic regression analysis was performed with or without T2D as the dependent variable. Consequently, it was suggested that the Lactobacillales population in the gut microbiota was positively associated with T2D, consistent with the results of case-control studies.
Conflicts of Interest Disclosure
The authors declare no competing interests.Downloads *Displays the aggregated results up to the previous day.
References
(1) Wang X, Zhang A, Miao J, Sun H, Yan G, Fang-fang Wu F, Wang X. 2018. Gut microbiota as important modulator of metabolism in health and disease. RSC Adv 8: 42380-42389.
(2) Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS. Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5: e9085.
(3) Sasaki M, Ogasawara N, Funaki Y, Mizuno M, Iida A, Goto C, Koikeda S, Kasugai K, Joh T. 2013. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study. BMC Gastroenterol 13: 81.
(4) Karlsson F, Tremaroli V, Nookaew I. Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. 2013. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498: 99-103.
(5) Remely M, Dworzak S, Hippe B, Zwielehner J, Aumüller E, Brath H, Haslberger A. 2013. Abundance and diversity of microbiota in type 2 diabetes and obesity. J Diabetes Metab 4: 253.
(6) Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, Komiya K, Kawaguchi M, Shimizu T, Ogihara T, Tamura Y, Sakurai Y, Yamamoto R, Mita T, Fujitani Y, Fukuda H, Nomoto K, Takahashi T, Asahara T, Hirose T, Nagata S, Yamashiro Y, Watada H. 2014. Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37: 2343-2350.
(7) Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015; 38: 159-165.
(8) Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmirid F, Mehrtashe A, Amirmozafari N. 2017. Comparison of gut microbiota in adult patients with type 2 diabetes. Microbial Pathogenesis 111: 362-369.
(9) Adachi K, Sugiyama T, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, Ebi M, Funaki Y, Ogasawara N, Goto C, Sasaki M, Kasugai K. 2019. Gut microbiota disorders cause type 2 diabetes mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects. J Clin Biochem Nutr 64: 231-238.
(10) Hashimoto Y, Hamaguchi M, Kaji A, Sakai R, Osaka T, Inoue R, Kashiwagi S, Mizushima K, Uchiyama K, Takagi T, Naito Y, Fukui M. 2020. Intake of sucrose affects gut dysbiosis in patients with type 2 diabetes. J Diabetes Investig 11:1623-1634.
(11) Nakaji S, Ihara K, Sawada K, Parodi S, Umeda T, Takahashi T, Murashita K, Kurauchi S, Tokuda I. 2021. Social innovation for life expectancy extension utilizing a platform-centered system used in the Iwaki health promotion project: A protocol paper. SAGE Open Medicine 9: 1–13.
(12) Nagashima K, Hisada T, Sato M, Mochizuki J. 2003. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 69: 1251-62.
(13) Nagashima K, Mochizuki J, Hisada T, Suzuki S, Shimomura K. 2006. Phylogenetic analysis of 16S ribosomal RNA gene sequences from human fecal microbiota and improved utility of terminal restriction fragment length polymorphism profiling. Biosci Microflora 25: 99-107.
(14) Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. 2014. Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing. PLoS ONE 9: e105592.
(15) Hisada T, Endoh K, Kuriki K. Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese. 2015. Arch Microbiol 197: 919-934.
(16) Kettle H, Louis P, Holtrop G, Duncan SH, Flint HJ. 2015. Modelling the emergent dynamics and major metabolites of the human colonic microbiota. Environ Microbiol 17: 1615-1630.
(17) Morita N, Umemoto E, Fujita S, Hayashi A, Kikuta J, Kimura I, Haneda T, Imai T, Inoue A, Mimuro H, Maeda Y, Kayama H, Okumura R, Aoki J, Okada N, Kida T, Ishii M, Nabeshima R, Takeda K. 2019. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature 566: 110-114.
(18) Kim M, Galan C, Hill AA, Wu W, Fehlner-Peach H, Song HW, Schady D, Bettini ML, Simpson KW, Longman RS, Littman DR, Diehl GE. 2018. Critical Role for the Microbiota in CX3CR1+Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses. Immunity 49: 151-163.
(19) Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nature Rev Immunol. 11: 98-107.
(20) Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, Wu H, Carreras A, Jeong H, Olofsson LE, Bergh P, Gerdes V, Hartstra A, de Brauw M, Perkins R, Nieuwdorp M, Bergström G, Bäckhed F. 2018. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175: 947–961.
(21) Shin AS, Gao X, Bohm M, Lin H, Gupta A, Nelson DE, Toh E, Teagarden S, Siwiec R, Dong Q, Wo JM. 2019. Characterization of proximal small intestinal microbiota in patients with suspected small intestinal bacterial overgrowth: A cross-sectional study. Clin Transl Gastroenterol 10:e00073.
(22) Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. 2015. Proton pump inhibitors alters specific taxa in the human gastrointestinal microbiome: A crossover trial. Gastroenterology 149: 883-885.
(23) Jackson MA, Goodrich JK, Maxan M, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. 2016. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65: 749-756.
(24) Otsuka T, Sugimoto M, Inoue R, Ohno M. 2017. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut 66: 1723-1725.
(25) Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C. 2012. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 70: 1070–1077.
(26) Ciardullo S, Rea F, Savaré L, Morabito G, Perseghin G, Corrao G. 2022. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results from a large population-based nested case-control study. J Clin Endocrinol Metab 107: e2671–e2679.
(27) Maeda T, Miki S, Morihara N, Kagawa Y. 2019. Aged garlic extract ameliorate fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. Exp Ther Med 18: 857-866.
Downloads
Posted
Submitted: 2022-06-27 01:54:04 UTC
Published: 2022-06-28 09:35:04 UTC — Updated on 2023-08-14 06:19:38 UTC
Versions
- 2023-08-14 06:19:38 UTC (5)
- 2023-03-10 09:52:12 UTC (4)
- 2022-12-13 06:49:17 UTC (3)
- 2022-11-28 05:37:54 UTC (2)
- 2022-06-28 09:35:04 UTC (1)
Reason(s) for revision
Some sentences (lines 142-158) were added . Refference (20) was added. The Word "healed" in line 55 of text and footnote of Table 1was revised to "ameliorated". A supplement file was added.License
Copyright (c) 2022
Koji Nagashima
Takayoshi Hisada
Jun Mochizuki
Tatsuya Mikami
Yoshinori Tamada
Shigeyuki Nakaji
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
